BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conway R, Nikiphorou E. Treating interstitial lung disease in rheumatoid arthritis - the embers of hope. Rheumatology (Oxford) 2020;59:3589-90. [PMID: 33068432 DOI: 10.1093/rheumatology/keaa516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Naučno-praktičeskaâ revmatologiâ 2022;60:517-534. [DOI: 10.47360/1995-4484-2022-1] [Reference Citation Analysis]
2 Gialouri CG, Fragoulis GE. Is there room for better screening for lung cancer in rheumatoid arthritis? RMD Open 2022;8. [PMID: 36597974 DOI: 10.1136/rmdopen-2022-002774] [Reference Citation Analysis]
3 Kelly C, Emery P, Dieudé P. Current issues in rheumatoid arthritis-associated interstitial lung disease. The Lancet Rheumatology 2021;3:e798-e807. [DOI: 10.1016/s2665-9913(21)00250-2] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cronin O, McKnight O, Keir L, Ralston SH, Hirani N, Harris H. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatol Int 2021;41:921-8. [PMID: 33721094 DOI: 10.1007/s00296-021-04835-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]